Articles

Addressing Ethical Issues in Cancer Care

By Phoebe Starr

TON - December 2020, Vol 13, No 6

"Ethical issues and dilemmas are inherent in our practice, especially at the end of life. Fortunately, we have professional codes and standards that serve to assist,” stated Joyce Neumann, PhD, APRN, AOCN, BMTCN, FAAN, Program Director, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, who spoke at the virtual Scripps MD Anderson Cancer Center’s 2020 Cancer Care Symposium. Read More ›

Multidisciplinary Cancer Care Should Start and End with the Patient

By Charlie Dawson

Quality Care Symposium

TON - December 2020, Vol 13, No 6

De-escalating Anger in Patients with Cancer

By Phoebe Starr

TON - December 2020, Vol 13, No 6

Anger is a basic human emotion and a natural response to stress. Healthcare professionals should anticipate that patients with cancer may feel and express anger and be prepared to deal with these scenarios. Read More ›

Xevinapant plus CRT Improves Survival in Patients with Locally Advanced HNSCC

By Patricia Stewart

Emerging Therapies

TON - December 2020, Vol 13, No 6

Sotorasib Demonstrates Promising Antitumor Activity in Patients with Advanced NSCLC

By Patricia Stewart

Emerging Therapies

TON - December 2020, Vol 13, No 6

CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

By Patricia Stewart

TON - December 2020, Vol 13, No 6

Aggressive Approach to High-Risk Smoldering Myeloma Gains Consensus

By Patricia Stewart

TON - December 2020, Vol 13, No 6

Explosion of New Regimens for Multiple Myeloma: Selecting the Right Option for the Right Patient

By Patricia Stewart

TON - December 2020, Vol 13, No 6

At the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, multiple myeloma expert Shaji Kumar, MD, discussed the “bonanza of treatment regimens for multiple myeloma.” Although several new treatments and combination regimens have extended survival in patients with multiple myeloma, this cancer remains an incurable chronic disease, he said. Read More ›

Novel Drug Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL

By William King

TON - December 2020, Vol 13, No 6

Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Page 106 of 376

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.